Expert Voices in Dementia

Sep 27 2024 12 ep. 7
Expert Voices in Dementia Podcast artwork

Thought leaders from the field present insights from dementia research, clinical practice, and caregiving that will help you maximize the quality of life and well-being of your patients

  Science  Health & Fitness  Education
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Kramer, Van Dyck

Sep 27 2024 12 mins  
Lynn D. Kramer, MD, FAAN, Chief Clinical Officer, Deep Human Biology Learning at Eisai and a member of the Eisai Executive Committee, and Christopher van Dyck, MD, Professor of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine, provide an overview of key results from the Clarity AD clinical trial assessing the safety and efficacy of lecanemab in people with early Alz

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 3

Sep 21 2024 10 mins  
In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this epi

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 2

Sep 21 2024 17 mins  
In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this epi

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 1

Sep 21 2024 8 mins  
In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this epi

Labcorp's Biomarker Testing for Alzheimer Disease

Sep 16 2024 12 mins  
Joseph M. Volpe, MD, Discipline Director, Clinical Neuroscience, Labcorp, discusses biomarker testing for Alzheimer disease and dementia,, including current offerings, reimbursement, and future directions in this evolving area. Learn more about your ad choices. Visit megaphone.fm/adchoices

What Neurologists Should Know About End-of-Life Care Discussions

Jul 19 2024 20 mins  
Dan Morhaim, MD, board-certified emergency medicine and internal medicine physician, and former 24-year Maryland State Legislator, highlights the importance of discussing end-of-life care issues with dementia patients and best practices for physicians to follow when broaching this topic. Learn more about your ad choices. Visit megaphone.fm/adchoices

Insights into the Role of Tau in Alzheimer Disease and Neurodegenerative Disorders

Jul 15 2024 22 mins  
Virginia Man-Yee Lee, PhD, who serves as the John H. Ware 3rd Endowed Professor in Alzheimer's Research at the University of Pennsylvania Perelman School of Medicine, the Director of the Center for Neurodegenerative Disease Research, and Co-Director of the Marian S. Ware Center for Alzheimer's Drug Discovery, presents an overview of tau biomarker testing and research. Learn more ab

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Jul 15 2024 9 mins  
Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss new findings on baseline characteristics about amyloid-related imaging abnormalities (ARIA) in people with Alzheimer disease treated with donanemab. Learn more about your ad choices. Visit megaphone.fm/adchoices

Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

Jul 15 2024 8 mins  
Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss recent data analyzing the real-world implications of donanemab treatment for people with Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices

Emerging Therapeutic Targets for Alzheimer Disease

Jul 15 2024 14 mins  
Howard Fillit, MD, geriatrician, neuroscientist, and Chief Science Officer and Co-Founder of the Alzheimer's Drug Discovery Foundation, discusses the importance of research into new therapeutic targets to develop next-generation treatments for Alzheimer disease, including small molecule compounds. Learn more about your ad choices. Visit megaphone.fm/adchoices